Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Zynerba_Pharmaceuticals
|
| gptkbp:formulation |
transdermal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zy T-101
|
| gptkbp:ingredients |
gptkb:cannabidiol
|
| gptkbp:regulatory_compliance |
investigational new drug
|
| gptkbp:route_of_administration |
topical
|
| gptkbp:targets |
gptkb:Dravet_syndrome
gptkb:Lennox-Gastaut_syndrome |
| gptkbp:used_for |
treatment of epilepsy
|
| gptkbp:bfsParent |
gptkb:Zy_Versa_Therapeutics
|
| gptkbp:bfsLayer |
6
|